RECENT ADVANCES OF Β-BLOCKERS AS DRUG REPURPOSING APPROACH: A SYSTEMATIC REVIEW | ||||
| Bulletin of Pharmaceutical Sciences Assiut University | ||||
| Volume 47, Issue 2, December 2024, Page 681-698 PDF (1.01 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfsa.2024.283788.2091 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Moaz A. Eltabeeb  1; Raghda Rabe Hamed1; Mohamed A. El-Nabarawi2; Mahmoud H. Teaima2; Menna M. Abdellatif1
| ||||
| 1Department of Industrial Pharmacy, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, Egypt | ||||
| 2Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt | ||||
| Abstract | ||||
| Repurposing pharmaceuticals is a potentially effective method in drug development to find novel therapeutic applications for already FDA-approved medications that deviate from their original intended usage. Compared with conventional methods of de novo drug discovery, it offers numerous benefits because it can drastically cut down on development time and medical expenses. In this review, the potential repurposing of β-blockers that have been previously authorized by the FDA for the management of cardiovascular disorders such as (hypertension, arrhythmias, and aortic dissection) was discussed. β-blockers have been shown to have encouraging anti-cancer, antibacterial, antimigraine, and spermicide properties in many experimental and epidemiological investigations. The outcomes have led to new drug indications or may lead to new drug indications. The objective of this review is to collect medications and their plausible modes of action that support repurposing, address difficulties in repositioning β-blockers for other disorders, and explore the possible therapeutic benefits of incorporating these medicines into nano-system formulations. | ||||
| Keywords | ||||
| Drug repurposing; Anti-hypertensive; B-blockers; Nano-systems | ||||
|
Statistics Article View: 628 PDF Download: 572 |
||||
